Fig. 2

ABHD5 expression and the benefit from FU-based adjuvant chemotherapy. a–d The StepMiner algorithm was used to stratify the population of 361 pMMR CRC patients (stage II/III) in the NCBI-GEO dataset into ABHD5^high and ABHD5^low subgroups, and the association of ABHD5 with prognosis and benefit from FU-based adjuvant chemotherapy was evaluated. a Three hundred and sixty-one pMMR CRC patients were stratified into ABHD5^high and ABHD5^low subgroups based on mRNA levels (StepMiner). b ABHD5^high tumors were significantly more likely to be BRAF mutant (BRAF MT) and p53 wild type (p53 WT) and CIN negative (CIN−), and ABHD5^low tumors were significantly more likely to be BRAF wild type (BRAF WT) and p53 mutant (p53 MT) and CIN positive (CIN+) (*p < 0.05, ***p < 0.001, χ²-test). c DFS in the subgroup of pMMR/ABHD5^low or pMMR/ABHD5^high who received surgery alone (Log-rank test). d DFS in pMMR/ABHD5^low or pMMR/ABHD5^high subgroup treated with or without FU-based adjuvant chemotherapy (Log-rank test, Cox proportional regression). e, f A human CRC tissue microarray containing 432 pMMR patient tumor samples from our hospital was analyzed. The samples were stratified into pMMR/ABHD5^high or pMMR/ABHD5^low subgroups based on the immunostaining score for MMR status and ABHD5 proficiency. e DFS in the subgroup of pMMR/ABHD5^low or pMMR/ABHD5^high who received surgery alone (Log-rank test). f DFS in the pMMR/ABHD5^low or pMMR/ABHD5^high subgroup treated with or without FU-based adjuvant chemotherapy (Log-rank test, Cox proportional regression)